The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving The Quantity, Quality, Relevance And Conduct Of Clinical Trials Of Medicines In Children.
Funder
National Health and Medical Research Council
Funding Amount
$102,576.00
Summary
I am a specialist clinical trials pharmacist focussed on the challenges associated with the conduct of medicinal trials in children. My intention is to collect evidence to determine the best strategies for improving the quantity, quality and relevance of clinical trials in children. This will help to ensure safe and effective age-appropriate drug therapies for children and improve the health outcomes of our children.
Application Of New Chemistry Approaches For Antimalarial Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$74,263.00
Summary
Malaria kills approximately one million people annually. Currently there no vaccine and many of the available drugs are becoming less effective due the resistance of this highly adaptable parasite. My aim is to develop new chemical classes of drugs that inhibit different targets in the malaria parasite to the currently available drugs. In addition to this I aim to improve the present systems for assessing antimalarial drug effects using new chemical approaches and live parasite assays.
SFRP4 As A Novel Diagnostic And Therapeutic Target For Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Gastric cancer is a common cancer with poor survival, but is and potentially curable when diagnosed at an early stage. However currently there are no non-invasive markers for the early detection of gastric cancer, and treatments for advanced cancer are limited. Secreted frizzled related protein 4 (SFRP4) is a protein that is thought to play a role in invasion of gastric cancer. This study will investigate the utility SFRP4 as a diagnostic test and possible therapeutic for gastric cancer.
Population-level Vaccine Safety Monitoring: Risk Assessment And Policy Implications
Funder
National Health and Medical Research Council
Funding Amount
$85,649.00
Summary
Vaccines prevent millions of deaths worldwide but events can occur after vaccination which may or may not be related to the vaccine. It is vital to ensure vaccines are safe and that both the public and medical providers remain confident in vaccination programs. The PhD thesis will look at the various methods for monitoring vaccine safety in Australia, and compare the usefulness of each system. This will provide information for policy makers on the safety of vaccines in Australia.
Molecular Epidemiology Of Mycobacterium Tuberculosis Infection In The Northern Territory, Australia
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
The Northern Territory (NT) of Australia has the highest jurisdiction-specific rates of tuberculosis (TB) in Australia, and TB is a disease that disproportionately affects Indigenous people. The factors that contribute to the spread of TB in the NT are incompletely understood. We plan to use technology known as “whole genome sequencing” of bacterial DNA to better the understanding of the spread of TB in the NT. This will help guide TB control policies.
Modern Chemical Exposures In Utero And In Infancy, And Their Impact Upon Early Neurodevelopmental Outcomes In The Barwon Infant Study, An Unselected Birth Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$138,353.00
Summary
I am a paediatric doctor interested in the effects of modern industrial chemicals on children’s development. Even in the womb babies are exposed to industrial chemicals and we know some, like lead, are harmful to developing brains. I am interested in other chemicals that are now suspected to affect development, including the polybrominated diphenyl esters (PBDEs), and I intend to investigate this as part of the Barwon Infant Study, which follows 1250 children from before birth to 3 years.
Dietary Therapies For The Treatment Of Drug-resistant Epilepsy
Funder
National Health and Medical Research Council
Funding Amount
$69,757.00
Summary
Epilepsy affects about 225,000 Australians, with 30% of suffers still experiencing seizures despite being on medications. A reduction in seizures can significantly improve the health of people with epilepsy who do not respond to medications. Low carbohydrate, high fat diets are a well-established treatment option in children, but this has not previously been studied in Australian adults. The aim of this research is to evaluate if dietary therapies are an effective treatment in adult epilepsy.
Hepatitis B Virus Drug Resistance: Impact On The Immunisation Program
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
ñAntiviral drug-associated vaccine escape mutantsî have the potential to jeopardize the hepatitis B immunization program. Which particular viral mutations or combination of mutations that can directly affect the clinical outcome of infection, especially in the context of vaccine induced immunity, are not known. In this study we will identify the clinical sequelae and public health consequences arising from the selection of these mutants.
Increasing Knowledge Of Mental And Physical Harms Among People Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$88,502.00
Summary
People who inject drugs (PWID) commonly experience a range of health problems. These include injecting-related injuries and non-viral diseases (e.g. endocarditis), drug overdose and mental health problems. With a focus on reducing the presence of these harms among the injecting population, the proposed research aims to better understand the factors that contribute to PWID experiencing, or not experiencing, such harms.
Novel Inhibition Of Cancer Cell Growth In Gastrointestinal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$47,474.00
Summary
This research project will focus on new treatment targets for gastrointestinal malignancies, focusing on the mTOR pathway which is important in driving cancer cell growth. The mTOR inhibitor drug Everolimus will be used in colon and biliary tract cancers to look for novel biomarkers of response and resistance to treatment, using cancer cell lines and correlative analysis with data obtained from patients' tumour samples and clinical assessment in current trials.